FDA Signs Off On "Authorized" Generics; Deals Are Pro-Competitive, Agency Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is not empowered to directly regulate the timing for marketing of previously approved drug products, the agency says in response to citizen petitions from Mylan and Teva. The two companies wanted FDA to prohibit the marketing of authorized generics during a first ANDA filer's 180-day exclusivity period.
You may also be interested in...
Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party
In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.
Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party
In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.
GPhA Talking To CMS About Medicaid "Best Price" For "Authorized" Generics
Federal and state governments are losing "substantial dollars" because innovators are not including authorized generics in their best price calculations for brand drugs, GPhA CEO Jaeger says. The group is highlighting the "inconsistency" in how FDA and the Centers for Medicare & Medicaid Services treat authorized generics.